New roots for AstraZeneca

Since taking over as chief executive last October, Pascal Soriot has been under pressure to turn round the fortunes of the Anglo-Swedish pharmaceutical group. He tells the FT's Andrew Jack about the restructuring and why the group has has decided to base its global headquarters in Cambridge.